{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:24:51Z","timestamp":1760077491009},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Immunosuppressants are commonly used in the treatment of neuromuscular diseases. The use of these medications requires health maintenance screening and monitoring for multiple potential sides effects, which may be best conducted when the prescribing physician and primary care physician work in tandem. Clinical practice guidelines, recommendations from professional organizations, prescription drug labeling, and expert opinion were reviewed and combined to provide recommendations for health maintenance for eight different immunosuppressants. Recommendations are provided for vaccinations, infection prophylaxis, laboratory monitoring, bone density screening, cancer screening, and other considerations. While studies in individuals with neuromuscular diseases are sparse, knowledge gained from the use of immunosuppressants in other conditions is applied in this review to provide recommendations to be used during the treatment of neuromuscular diseases in adults. <jats:italic>Muscle Nerve<\/jats:italic> 59:397\u2013403, 2019<\/jats:p>","DOI":"10.1002\/mus.26382","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T15:58:37Z","timestamp":1541865517000},"page":"397-403","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Health maintenance for adults with neuromuscular diseases on immunosuppression"],"prefix":"10.1002","volume":"59","author":[{"given":"Sarah L.","family":"Cartwright","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine Wake Forest School of Medicine  Winston\u2010Salem North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Cartwright","sequence":"additional","affiliation":[{"name":"Department of Neurology Wake Forest School of Medicine  Winston\u2010Salem North Carolina, 27157 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550220162021"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26032"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126579"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.396"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit816"},{"key":"e_1_2_9_7_1","unstructured":"CDC Vaccine Recommendations in Altered Immunocompetence [Internet]. [cited September 20 2018]. Available at:https:\/\/www.cdc.gov\/vaccines\/hcp\/acip\u2010recs\/general\u2010recs\/immunocompetence.html. Accessed November 15 2018."},{"key":"e_1_2_9_8_1","unstructured":"CDC Pneumococcal Vacinnation [Internet]. [cited September 20 2018]. Available at:https:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/hcp\/who-when-to-vaccinate.html. Accessed November 15 2018."},{"key":"e_1_2_9_9_1","unstructured":"Eculizumab Prescription Drug Labeling [Internet]. [cited September 20 2018]. Available at:http:\/\/alexion.com\/Documents\/Soliris_USPI.aspx. Accessed November 15 2018."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032588"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2008-740ST"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212588"},{"key":"e_1_2_9_13_1","first-page":"1186","article-title":"Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus","volume":"23","author":"Kadoya A","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_9_14_1","unstructured":"Prednisone Prescription Drug Labeling [Internet]. [cited September 20 2018]. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202020s000lbl.pdf. Accessed November 15 2018."},{"key":"e_1_2_9_15_1","unstructured":"Deflazacort Prescription Drug Labeling [Internet]. [cited September 20 2018]. Available at:https:\/\/www.emflaza.com\/wp-content\/themes\/emflaza-patient\/pdf\/prescribing_information.pdf. Accessed November 15 2018."},{"key":"e_1_2_9_16_1","unstructured":"Azathioprine Prescription Dug Labeling [Internet]. [cited September 20 2018]. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/016324s034s035lbl.pdf. Accessed November 15 2018."},{"key":"e_1_2_9_17_1","unstructured":"Mycophenolate Mofetil Prescription Drug Labeling [Internet]. [cited September 20 2018]. Available at:https:\/\/www.gene.com\/download\/pdf\/cellcept_prescribing.pdf. Accessed November 15 2018."},{"key":"e_1_2_9_18_1","unstructured":"Methotrexate Prescription Drug Labeling [Internet]. [cited September 20 2018]. Available at:https:\/\/www.otrexup.com\/files\/2215\/2834\/7000\/Otrexup_Prescribing_Information.pdf. Accessed November 15 2018."},{"key":"e_1_2_9_19_1","unstructured":"Rituximab Prescription Drug Labeling [Internet]. [cited September 20 2018]. Available at:https:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf. Accessed November 15 2018."},{"key":"e_1_2_9_20_1","unstructured":"Cyclosporine Prescription Drug Labeling [Internet]. [cited September 20 2018]. Available at:https:\/\/www.rxabbvie.com\/pdf\/gengraf-cap.pdf. Accessed November 15 2018."},{"key":"e_1_2_9_21_1","unstructured":"Cyclophosphamide Prescription Drug Labeling [Internet]. [cited September 20 2018]. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/012141s090 012142s112lbl.pdf. Accessed November 15 2018."},{"key":"e_1_2_9_22_1","unstructured":"USPSTF Human Immunodeficiency Virus (HIV)infection: screening [Internet]. [cited 2018 Sep 20]. Available at:https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/UpdateSummaryFinal\/human\u2010immunodeficiency\u2010virus\u2010hiv\u2010infection\u2010screening?ds=1&s=hiv. Accessed November 15 2018."},{"key":"e_1_2_9_23_1","unstructured":"USPSTF Hepatitis C: Screening [Internet]. [cited September 20 2018]. Available at:https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/UpdateSummaryFinal\/hepatitis-c-screening?ds=1&s=hepatitis%20c. Accessed November 15 2018."},{"key":"e_1_2_9_24_1","first-page":"909","volume":"70","author":"Buch MH1","year":"2011","journal-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23279"},{"key":"e_1_2_9_26_1","unstructured":"FRAX Tool [Internet]. [cited September 20 2018]. Available at:https:\/\/www.sheffield.ac.uk\/FRAX\/. Accessed November 15 2018."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0085-5"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001708"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61050-2"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70271-1"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v03n0104"},{"key":"e_1_2_9_33_1","first-page":"713","article-title":"The new pregnancy and lactation labeling rule","volume":"41","author":"Pernia S","year":"2016","journal-title":"P T"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000001659"},{"issue":"12","key":"e_1_2_9_35_1","first-page":"CD002243","article-title":"Corticosteroids for treating sepsis","author":"Annane D","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1659-4"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.26382","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.26382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:09:42Z","timestamp":1694401782000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.26382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,21]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1002\/mus.26382"],"URL":"https:\/\/doi.org\/10.1002\/mus.26382","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,21]]},"assertion":[{"value":"2018-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}